Viatris climbs after raising lower end of annual revenue forecast

Viatris

06/08/2026 12:40

** Shares of drugmaker Viatris VTRS.O rise 2% to $18 premarket
** Co reports Q2 adj. profit of 69 cents/shr vs analysts' average estimate of 60 cents/shr, according to LSEG data
** VTRS' Q2 revenue of $3.76 billion beats analysts' average expectation of $3.68 billion, helped by strong demand for its branded drugs and strength in Greater China region
** Co expects annual revenue of $14.55 billion to $14.95 billion compared to its previous expectation between $14.45 billion to $14.95 billion
** Co expects annual adj. profit per share of $2.45 to $2.59 vs its prior estimate of $2.33 and $2.47
** Up to last close, stock up 41.8% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))